EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

ADMA Biologics Inc (ADMA) had EBITDA of $64.96M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$139.16M
Net Income	$49.38M
Cost of Goods Sold	$50.35M
Gross Profit	$88.81M
Operating Expenses	$76.41M
Operating Income	$62.75M
Non-Operating Income/Expense	$-1.16M
Pre-Tax Income	$61.59M
Normalized Pre-Tax Income	$61.59M
Income after Taxes	$49.38M
Income from Continuous Operations	$49.38M
Consolidated Net Income/Loss	$49.38M
Normalized Income after Taxes	$49.38M
EBIT	$62.75M
EBITDA	$64.96M
Weighted-Average Shares Outstanding (Basic)	238.30M
Weighted-Average Shares Outstanding (Diluted)	244.91M
Earnings per Share (EPS) (Basic)	$0.22
Earnings per Share (EPS) (Diluted)	$0.20
Balance Sheet Financials
Current Assets	$466.51M
Property, Plant, and Equipment	$65.06M
Long-Term Assets	$157.73M
Total Assets	$624.24M
Current Liabilities	$69.54M
Long-Term Debt	$75.98M
Long-Term Liabilities	$77.38M
Total Liabilities	$146.92M
Common Equity	$477.32M
Tangible Shareholders Equity	$473.16M
Shareholders Equity	$477.32M
Common Shares Outstanding	237.87M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$50.40M
Cash Flow from Investing Activities	$-21.89M
Cash Flow from Financial Activities	$-44.02M
Beginning Cash	$103.15M
End Cash	$87.63M
Increase/Decrease in Cash	$-15.52M
Stock-Based Compensation	$20.03M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.71
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.14
Debt to Equity Ratio	0.17
Gross Margin	63.82%
Operating Margin	45.09%
EBIT Margin	45.09%
EBITDA Margin	--
Pre-Tax Profit Margin	44.26%
Profit Margin	35.48%
Free Cash Flow	$27.82M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.24
Receiveable Turnover	0.88
Days Sales in Receivables	102.46
Return on Equity	10.35%
Return on Tangible Equity	10.44%
Return on Assets	7.91%
Return on Investments	8.92%
Book Value Per Share	$2.01
Free Cash Flow per Share	$0.11
Operating Cash Flow per Share	$0.21

Data from Zacks Investment Research, Inc.